Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 366

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 366
---
inical and clinical studies, execution and integration
of business development transactions, manufacturing, regulatory and quality requirements of the healthcare markets, and market launch
and commercialization of major medical products. We believe our management team has the required background and skill sets to execute on the Company’s business strategy.
Additionally, our team has a proven history of raising financing in support of our product candidates.

| 15 | World Population Prospects: 2022 Revision, Population ages                                                                                                        
 65 and above (% of total population), United Nations Population Division. https://data.worldbank.org/indicator/ SP.POP.65UP.TO.ZS?end=2022&start=1960&view=chart. |

| 194 |

Our Growth Strategy

Our goal is to
become a fully integrated biopharmaceutical company focused on the advancement of new technologies across therapeutics, monitoring and
digital health that address diseases associated with aging. To achieve this objective, we intend to build on our initial platform of therapeutic
technologies by opportunistically acquiring and/or partnering with other health technology companies to become a leading provider and
consolidator of products and services designed to increase and improve health span amongst the rapidly growing aging patient population.
Specifically, we aim to establish a fully-integrated portfolio of longevity-related products and services by:

| ● | Advancing our portfolio of existing therapeutic product candidates to FDA approval and commercial launch; |

| ● | Expanding into other therapeutic indications using our current technology platforms; |

| ● | Acquiring or partnering with high-quality companies, technologies and services in the longevity field; |

| ● | Establishing a digital health management services platform and offering value-added health management 
 services to a broad distribution of healthcare customers; and                                         |

| ● | Optimizing our service offerings and user experience to expand the scale of our users. |

Team and Innovation History

We are led by
a highly accomplished, multidisciplinary management team with extensive experience and strong expertise in all phases of therapeutic product
development to include translational science, pre- clinical and clinical development, regulatory affairs and business development. Our
senior management team has over 125 years of combined experience, with an average tenure of 25 years in the development and commercialization
of medtech and biopharmaceutical innovations for numerous clinical indications. Our team’s expertise includes clinical need and
market analysis, product design and intellectual property generation, clinical and regulatory execution, as well as supply chain and quality
system development. Members of the senior management team